m+Medelevator.RU
← Поиск публикаций
Journal of virology · 2026

HSV-1 UL42 and UL47 hijack cellular nucleotide synthetic enzyme CAD to promote lytic replication.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Qin Chao, Xie Xinchi, Xie Taolin, An Zhenhao, Chung Woo-Chang, Feng Pinghui

Аннотация

Cellular metabolic enzymes are well defined for their roles in metabolism, and their function beyond metabolism is poorly defined. Here, we report that herpes simplex virus 1 (HSV-1) couples evasion of the inflammatory response to metabolic activation to promote lytic replication. Specifically, HSV-1 activates carbamoyl-phosphate synthetase, aspartate transcarbamoylase, and dihydroorotase (CAD), which catalyzes the rate-limiting steps of de novo pyrimidine synthesis. Activated CAD not only fuels de novo nucleotide synthesis but also deamidates RelA. RelA deamidation suppresses NF-κB activation and the inflammatory response while simultaneously upregulating key glycolytic enzymes to promote aerobic glycolysis. Further affinity purification and functional assays identified HSV-1 UL42 and UL47 that interact with and activate CAD, recapitulating the phenotypes of RelA deamidation. Collectively, our work uncovers a role for a metabolic enzyme in coupling immune evasion to metabolic activation through its protein deamidase activity during HSV-1 infection, highlighting a potential therapeutic target.IMPORTANCEHost immune defense and cellular metabolism are two fundamental processes that shape viral pathogenesis. Here, we revealed that herpes simplex virus 1 (HSV-1) activates a nucleotide synthetic enzyme not only to support nucleotide synthesis but also to exploit its unconventional activity for immune evasion and metabolic reprogramming, highlighting a potential therapeutic target.